newsfilter
← Latest News
Business Wire·

Sesen Bio Expands CMC and Clinical Teams

Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its chemistry, manufacturing, and control (CMC) and clinical development t